ALS Patient Uses Synchron Brain-Chip Interface to Control Smart Devices Through Thought
Synchron has announced one of its patients with ALS is now able to control devices using only his mind with the company's brain chip implant.
Brain implant lets man with amyotrophic lateral sclerosis control Amazon's Alexa with his thoughts
A patient with a degenerative disease was able to command Amazon's Alexa digital assistant with his mind, the company behind the
Brain implant allows ALS patient to control Amazon’s Alexa with thought: ‘Gives me back the independence that I’m losing’
To be able to manage important aspects of my environment and control access to entertainment gives me back the independence that I’m losing.”
Synchron Connects Brain Implant to Amazon Alexa
Synchron is one of several companies working to make brain-computer interfaces (BCIs) a reality. Earlier this summer, Synchron revealed one of its study participants could use the Apple Vision Pro VR headset thanks to the Synchron implant.
64-year-old ALS patient controls Alexa with just his thoughts
A 64-year-old ALS patient successfully controlled Alexa using his thoughts through a brain implant, allowing him to perform tasks like making video calls, playing music, and operating smart home devices.
Man controls Amazon Alexa with his thoughts, ‘It gives me back the independence’
An ALS patient manipulated Amazon's Alexa through a brain implant, enabling him to control devices and stream shows mentally. This advancement illustrates the potential of brain-computer interfaces to provide independence to those with degenerative diseases,
ALS patient uses brain chip to control Alexa, shop, stream with just thoughts
On Monday, Synchron, a brain-computer interface (BCI) company, announced this development, revealing that the 64-year-old patient, diagnosed with amyotrophic lateral sclerosis (ALS), can stream shows,
FierceBiotech5h
After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule
Athira Pharma has been on a bumpy road in recent years, and now the company is restructuring and shedding weight to try to ...
New research identifies potential therapeutic target for amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is the most common degenerative motor neuron disease ...
News Medical on MSN7d
New blood test achieves 98% accuracy in diagnosing ALS
A highly accurate diagnostic blood test has been developed for amyotrophic lateral sclerosis (ALS), a progressive ...
Prince William and Kate Middleton Support New Book About Late Rugby Star Who Died From ALS
Prince William and Kate Middleton have offered their support to Lindsey Burrow, the widow of late British rugby star Rob ...
The Lancet23h
Trial designs for motor neuron disease in the 21st century
Motor neuron diseases are a group of progressive and ultimately fatal neurodegenerative disorders of the motor system, ...
Pharmaceutical Technology11d
Fasudil by Woolsey Pharmaceuticals for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Fasudil is under clinical development by Woolsey Pharmaceuticals and currently in Phase II for Amyotrophic Lateral Sclerosis.
Daily9d
Zydus Lifesciences completes Phase II(a) clinical trial of Usnoflast in patients with Amyotrophic Lateral Sclerosis
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company, announced the completion of its Phase II(a) clinical ...
USA Today on MSN4d
Steve Gleason 'stable' after medical event during hurricane: What we know
Gleason, who was diagnosed with amyotrophic lateral sclerosis (ALS) in 2011 when he was 33 years old, has become an ...
Pharmaceutical Technology11d
Siplizumab by ITB-Med for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Siplizumab is under clinical development by ITB-Med and currently in Phase I for Amyotrophic Lateral Sclerosis.